Meeting Banner
Abstract #1680

Gd-Complex of Macrocyclic DTPA Conjugate of 2,2-Diaminobiphenyl: A New MR Contrast Agent for both Angiography & Brain-Tumor Imaging

Ki-Hye Jung1, Hee-Kyung Kim2, Min-Kyoung Kang2, Ji-Ae Park3, Seung-Tae Woo4, Joo-Hyun Kim4, Tae-Jeong Kim1, Yongmin Chang2,5

1Department of Applied Chemistry, Kyungpook National University, Daegu, Korea, Republic of; 2Department of Medical & Biological Engineering, Kyungpook National University, Daegu, Korea, Republic of; 3Laboratory of Nuclear Medicine Research, Molecular Imaging Center, Korea Institute of Radiological & Medical Science, Seoul, Korea, Republic of; 4Bayer Schering Pharma Korea, Seoul, Korea, Republic of; 5Department of Diagnostic Radiology and Molecular Medicine, Kyungpook National University, Daegu, Korea, Republic of

We report the synthesis of Gd-complex of macrocyclic DTPA conjugate of 2,2-diaminobiphenyl (GdL) for use as a new MR contrast agent for both angiography and brain-tumor imaging. GdL exhibits very high R1 relaxivity (= 12.15 mM-1sec-1) which is 3.3 times as high as that of structurally related macrocyclic analogue, Dotarem R1(= 3.7 mM-1sec-1). Also observed is the greater kinetic stability than those of commercially available Omniscan and Multihance. The present system shows a very strong blood-pool effect for as long as 2 h, and most uniquely demonstrates brain-tumor imaging capability which is absent from the ordinary ECF MRI CAs.